Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.81 |
| ▸ | NAMPT | P43490 | 8/20 | 0.67 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | NPC1 | O15118 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30361493 | 1.00 | TSHR (0.81) | TSHRNAMPTGAAMAPTNPC1 | |
| SCHEMBL23747809 | 0.86 | TSHR (0.60) | TSHRNAMPTGAAMAPTNPC1 | |
| SCHEMBL23747792 | 0.85 | NAMPT (0.66) | TSHRNAMPTGAANPC1KMT2A | |
| SCHEMBL30361410 | 0.85 | NAMPT (0.66) | TSHRNAMPTGAANPC1KMT2A | |
| SCHEMBL26101409 | 0.85 | NAMPT (0.81) | NAMPTNPC1POLBRAB9A | |
| SCHEMBL20379441 | 0.85 | NAMPT (0.86) | NAMPTNPC1KMT2APOLBMEN1 | |
| SCHEMBL26098750 | 0.85 | RAB9A (0.66) | NAMPTNPC1KMT2APOLBMEN1 | |
| SCHEMBL23747734 | 0.84 | NAMPT (0.66) | NAMPTNPC1KMT2APOLBMEN1 | |
| SCHEMBL30361424 | 0.84 | NAMPT (0.66) | NAMPTNPC1KMT2APOLBMEN1 | |
| SCHEMBL20379630 | 0.84 | NAMPT (0.88) | NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230133132-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230133132-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230133132-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-05-04 | — | — | US | disclosed |
| WO-2021159015-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133132-A1 | NAMPT MODULATORS | NAMPT, MC4R, SIRT1 | TSHR 562/4885NAMPT 1/4885GAA 2947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.